Henry Skinner has been appointed as the first CEO of the AMR Action Fund
The AMR Action Fund is aiming to strengthen and accelerate antibiotic development
Henry Skinner (pictured above) has been appointed the first chief executive officer of the AMR Action Fund, an initiative aiming to strengthen and accelerate antibiotic development.
Skinner joins the AMR Action Fund with extensive biomedical and investment funding experience, having spent decades in the biomedical research, venture and the pharmaceutical industries.
Most recently, he served as the senior vice president of venture at Tekla Capital Management.
Prior to that, he has served as vice president and deputy head and managing director of the Novartis Venture Fund, as well as executive director, head strategic alliances at Novartis Institutes for Biomedical Research.
(3)
Project brings together Novartis drug discovery and gene therapy expertise and funding support from the Gates Foundation
Agreement aims to address disparity in access to treatments and to prioritize populations and regions that bear the
greatest burden of sickle cell disease in the search for curative therapies
Effort expands on Novartis commitment to sickle cell disease, which includes a therapeutic pipeline and a holistic approach to diagnosis, treatment, and management of the disease in sub-Saharan Africa
Basel, February 17, 2021 - Novartis today announced that it has entered into a grant agreement with the Bill & Melinda Gates Foundation. As part of the agreement, the foundation will provide funding support for the discovery and development of a single-administration,
BASEL, SWITZERLAND,
February 17, 2021 /3BL Media/ Novartis today announced that it has entered into a grant agreement with the Bill & Melinda Gates Foundation. As part of the agreement, the foundation will provide funding support for the discovery and development of a single-administration,
in vivo gene therapy to cure sickle cell disease (SCD). The project brings together Novartis drug discovery and gene therapy expertise with the Gates Foundation’s charitable objectives to expand access to healthcare in low-resource settings in an effort to address this potentially life-threatening genetic disease.
“Existing gene therapy approaches to sickle cell disease are difficult to deliver at scale and there are obstacles to reaching the vast majority of those affected by this debilitating disease,” said Jay Bradner, a hematologist and President of the Novartis Institutes for BioMedical Research (NIBR). “This is a challenge that calls for collective action, and we are thrill
Radiation-Resistant Cancer Cells Can Be Killed Using Drug That Coaxes Persistent p53 Signaling
February 17, 2021
Share
All tissues are not equally sensitive to radiation. It has long been recognized that the well-known tumor suppressor protein and transcription factor p53 is linked to the degree of a tissue’s sensitivity to radiation. Yet how p53 regulates vulnerability to radiation has been elusive so far.
In an article titled “
Nature Communications, scientists at the Blavatnik Institute at Harvard Medical School, Massachusetts General Hospital, and the Novartis Institutes for BioMedical Research clarify that it is not the abundance of p53 protein in a tissue’s that correlates with the tissues’ sensitivity to radiation but the dynamics of p53 signaling following radiation.
Novartis, Gates Foundation pursue a simpler gene therapy for sickle cell statnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from statnews.com Daily Mail and Mail on Sunday newspapers.